Pacira BioSciences, Inc.

Valuation Analysis

About the Company

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medici

Pacira BioSciences, Inc. Stock at a Glance

Pacira BioSciences, Inc. (PCRX) is currently trading at $22.99 with a market capitalization of $904.6M. The trailing P/E ratio stands at 176.85x, with a forward P/E of 6.3x. The 52-week range spans from $18.80 to $27.64; the current price is 16.8% below the yearly high. Year-over-year revenue growth stands at +5.0%. The net profit margin stands at 0.7%.

💰 Dividend

Pacira BioSciences, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

6 analysts rate Pacira BioSciences, Inc. (PCRX) on consensus: Buy. The average price target is $29.67, implying +29.04% from the current price. Analyst price targets range from $23.00 to $38.00.

Pacira BioSciences, Inc.: The Investment Case in Detail

Pacira BioSciences, Inc. (PCRX) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 79.33%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 29.04% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

With a net margin of just 0.7%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 24.24% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

At a PEG of 11.21, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 9.18x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 6.3x is meaningfully below the trailing 176.85x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 29.04% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (24.24%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Pacira BioSciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.